Journal article
Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221
Abstract
PURPOSE: Monalizumab binds CD94/NKG2A, preventing HLA-E inhibition of tumor lymphocytes. A dose-ranging/cohort expansion trial of monalizumab for recurrent gynecologic malignancies was conducted to determine the recommended phase II dose (RP2D) and to explore clinical activity, pharmacokinetics, pharmacodynamics, safety, and immunogenicity.
PATIENTS AND METHODS: Participants (and part 2 expansion cohorts) included (i) platinum-sensitive …
Authors
Tinker AV; Hirte HW; Provencher D; Butler M; Ritter H; Tu D; Azim HA; Paralejas P; Grenier N; Hahn S-A
Journal
Clinical Cancer Research, Vol. 25, No. 20, pp. 6052–6060
Publisher
American Association for Cancer Research (AACR)
Publication Date
October 15, 2019
DOI
10.1158/1078-0432.ccr-19-0298
ISSN
1078-0432
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Abdominal PainAdministration, IntravenousAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCanadaCohort StudiesDose-Response Relationship, DrugDrug Administration ScheduleDrug Resistance, NeoplasmEndometrial NeoplasmsFatigueFemaleHumansMiddle AgedNauseaNeoplasm Recurrence, LocalNeoplasm StagingOvarian NeoplasmsResponse Evaluation Criteria in Solid TumorsUterine Cervical NeoplasmsVomiting